Department of Pharmaceuticals is implementing Production Linked Incentive Scheme for Pharmaceuticals with a total financial outlay of Rs. 15,000 crore
Department of Pharmaceuticals is implementing Production Linked Incentive Scheme for Pharmaceuticals with a total financial outlay of Rs. 15,000 crore
The Department of Pharmaceuticals is implementing the Production Linked Incentive (PLI) Scheme for Pharmaceuticals with a total financial outlay of Rs. 15,000 crore and scheme tenure up to FY 2027-28. The scheme provides for financial incentive to 55 selected applicants for manufacturing of identified products under three categories for a period of six years. The product Category 1 covers drugs such as bio-pharmaceuticals, complex generics, gene therapy drugs, complex excipients, orphan drugs etc. Orphan drugs are those drugs which are used for treatment of rare diseases. Under the scheme, total 8 orphan drugs have been approved for manufacturing. The orphan drugs approved under the PLI scheme for Pharmaceuticals are as follows:
S. No.
Name of the product
Usage
1
Nitisinone
Treatment of Hereditary Tyrosinemia Type 1
2
Nusinersen
Treatment of Spinal Muscular Atrophy
3
Rufinamide
Treatment of Lennox-Gastaut syndrome.
4
Sodium Phenyl Butyrate
Treatment of Urea Cycle Disorders
5
Tiopronin
Prevention of Cystine Nephrolithiasis
6
Trientine Hydrochloride
Treatment of Wilson’s disease
7
Eliglustat
Treatment of Gaucher’s disease
8
Cannabidiol
Treatment of Dravet-Lennox Gastaut syndrome
This information was given by the Union Minister of State for Chemicals and Fertilizers Smt Anupriya Patel in Lok Sabha in reply to a question today.
*****